Pure Global
NCT04657341

Sonazoid Contrast-enhanced Ultrasound in Assessing Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer Patients.

Chinese PLA General Hospital·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ultrasound
Study type
Observational
Sponsor & location
Primary sponsor
Chinese PLA General Hospital
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Aug 01, 2020
End date
Dec 01, 2021
Enrollment
1012 participants
Primary outcome

Sonazoid contrast-enhanced ultrasound in assessing effectiveness of neoadjuvant chemotherapy in breast cancer patients.

Summary

Sonazoid as a new generation of ultrasound contrast agent.This study based on the features of
 Sonazoid specific angiography and high mechanical index,the role of Sonazoid in assessing
 effectiveness of neoadjuvant chemotherapy in breast cancer patients was explored.

ICD-10 classifications
Abnormal ultrasonic finding on antenatal screening of motherAntenatal screening for malformations using ultrasound and other physical methodsAntenatal screening for fetal growth retardation using ultrasound and other physical methodsOther diagnostic agentsExamination of ears and hearing
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04657341
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04657341 through Pure Global AI's free database. This phase not specified trial is sponsored by Chinese PLA General Hospital and is currently Not yet recruiting. The study focuses on Ultrasound. Target enrollment is 1012 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.